G.ST Antivirals Begins Phase II Trial and Names Ronald Bruce Turner Chief Medical Officer

G.ST Antivirals, engaged in the development of innovative antivirals, announced the commencement of its Phase II trial on April 2nd, 2024, and the appointment of Ronald Bruce Turner as its new Chief Medical Officer (CMO). The company focuses on creating broad-spectrum antivirals for respiratory infections, employing host cell-based strategies. The lead product, a nasal spray containing 2-Deoxy-D-glucose (2-DG), targets a range of viruses including rhinoviruses and coronaviruses. The ongoing Phase II study, a double-blind and placebo-controlled trial, occurs in the Netherlands at the Centre for Human Drug Research (CHDR), aiming to evaluate the efficacy and safety of 2-DG in preventing or mitigating respiratory diseases.

Dr. Guido Gualdoni, CEO of G.ST Antivirals, expressed enthusiasm for both the trial's progress and Dr. Turner's joining. Turner, a renowned expert in respiratory virus research, transitions from a scientific advisory role to CMO, where he will guide the clinical trajectory of 2-DG. His vast experience encompasses roles at the University of Virginia and contributions to prestigious medical journals and research. G.ST Antivirals' strategy relies on inhibiting host cell metabolism changes induced by viruses, effectively starving the viruses to impede their replication.